RecruitingPhase 2NCT06985147

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)

Sponsor

Disc Medicine, Inc

Enrollment

60 participants

Start Date

Aug 12, 2025

Study Type

INTERVENTIONAL

Conditions

Polycythemia Vera (PV)

Summary

This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DISC-3405 for people with polycythemia vera (pv). The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDISC-3405

DISC-3405 is administered subcutaneously.

Locations(15)

Mayo Clinic in Arizona

Phoenix, Arizona, United States

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

UCLA Health

Los Angeles, California, United States

Keck Medicine of USC - Cancer Clinic- Newport Beach

Newport Beach, California, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Mayo Clinic in Minnesota

Rochester, Minnesota, United States

Siteman Cancer Center - Washington University St. Louis

St Louis, Missouri, United States

Atrium Health - Levine Cancer Center

Charlotte, North Carolina, United States

Duke University

Durham, North Carolina, United States

Atrium Health Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

MD Anderson Cancer Center

Houston, Texas, United States

University of Washington - Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06985147

Related Trials

A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV

NCT074458931 location

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

NCT074698915 locations

Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

NCT072322901 location

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT073622252 locations

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

NCT065412491 location